LAIYANG, China, Sept. 29 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (“Genesis” or the “Company”), a U.S. pharmaceutical company with its principal operations in the People’s Republic of China, today announced that the Company will host a conference call at 9:00 a.m. Eastern on Wednesday, October 1, 2008 to discuss financial results for its fourth quarter and fiscal year ended June 30, 2008.
Conference Call
Genesis Pharmaceuticals management will host a conference call at 9:00 a.m. Eastern on Wednesday, October 1, 2008 to discuss financial results for its fourth quarter and fiscal year 2008 ended June 30, 2008. The conference call will include Mr. Wubo Cao, Chairman and CEO, and Ms. Elsa Sung, CFO. To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888) 419-5570. International callers should call (617) 896-9871. The Conference Passcode is 375 022 62. If you are unable to participate in the call at that time, replay of the conference call will be available from Wednesday, October 1 at 11:00 a.m. Eastern until Wednesday, October 15. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The Conference Passcode is 31221366.
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People’s Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule and granule form. The Company maintains a representative office in the U.S.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.
CONTACT: Elsa Sung, CFO, Genesis Pharmaceuticals Enterprises, Inc.,
+1-561-988-9880, or genesispharm@gmail.com; or Crocker Coulson, President,
CCG Investor Relations, Inc., +1-646-213-1915, or crocker.coulson@ccgir.com
Web site: http://www.genesis-china.net/
http://www.ccgir.com/
